TOPICS

Customer Acquisition Cost (CAC) for Medical Devices & MedTech

DIRECT ANSWER

Customer acquisition cost (CAC) is the total sales and marketing spend required to acquire one new paying customer, calculated as total acquisition spend divided by new customers acquired in the same period. It is a primary efficiency metric for growth teams, typically evaluated alongside LTV to determine whether customer economics are sustainable. For Medical Devices & MedTech companies, this matters because Hospital value analysis committee (VAC) reviews are the primary purchase gate for capital equipment and novel devices — a device that has clinical champion support but fails economic justification (no published cost-effectiveness data, no reimbursement code, no comparable reduction in length of stay) does not get approved.

What customer acquisition cost (cac) means for Medical Devices & MedTech

Medical device marketing that drives adoption requires simultaneous execution on three tracks: clinical evidence (peer-reviewed publications, society presentation abstracts, clinical registry participation), economic justification (published health economic analyses, cost-per-procedure comparisons, length-of-stay impact), and reimbursement support (CPT code coverage, coverage determination letters, payer medical policies). Skipping any track creates a sales ceiling that no campaign can overcome. Sunshine Act-compliant KOL relationship management — where physician education funding and speaking fees are properly documented and reported — is both a compliance requirement and a marketing asset: disclosed, transparent relationships with recognized clinical experts build more credibility than undisclosed ones.

For Medical Devices & MedTech teams the relevant marketing pains are: Hospital value analysis committee (VAC) reviews are the primary purchase gate for capital equipment and novel devices — a device that has clinical champion support but fails economic justification (no published cost-effectiveness data, no reimbursement code, no comparable reduction in length of stay) does not get approved; GPO (Group Purchasing Organization) contract coverage is prerequisite for reaching most US hospital systems at scale — marketing to hospitals not on your GPO contract generates clinical interest that procurement can't fulfill, wasting sales resources on unconvertible prospects; FDA clearance and approval claims require extraordinary precision — marketing materials must use only cleared indications, cannot imply off-label use, and must include required device labeling language even in digital ad formats where character limits are real; Clinical evidence generation is a long-cycle investment (3–7 years for RCT evidence) that competes with short-cycle commercial pressure — medtech companies that don't invest in evidence early face a permanent credibility ceiling against competitors who did; Physician preference and KOL endorsement drive adoption in surgical and interventional specialties, but KOL relationships are subject to Sunshine Act reporting requirements that create compliance exposure if not managed correctly. FDA 21 CFR Part 807 (510(k) clearance process); FDA 21 CFR Part 814 (PMA process for Class III devices); FDA Off-Label Promotion prohibition (device labeling and promotion must match cleared indications); Physician Payments Sunshine Act (Open Payments) reporting for physician KOL relationships; Anti-Kickback Statute implications for device incentives; HIPAA for any patient data used in clinical studies; EU MDR (Medical Device Regulation) and IVDR for European device marketing; ISO 13485 quality system certification as marketing credibility signal; GDPR for clinical study and registry data involving EU patients

How to calculate CAC and what it includes

The standard CAC formula is: total sales and marketing spend ÷ number of new customers acquired, measured over the same time period (monthly or quarterly). Fully-loaded CAC includes salaries and benefits for sales and marketing staff, agency and contractor fees, ad spend, tool and software costs, and event costs — not just media spend. Blended CAC mixes all channels; paid CAC isolates spend on paid acquisition only. Both are useful; the distinction matters when evaluating channel efficiency.

SaaS benchmarks vary significantly by segment. According to OpenView's 2024 SaaS Benchmarks report, median CAC for PLG (product-led growth) SaaS companies is $200–$500; for sales-led SMB SaaS, $800–$2,000; for mid-market, $3,000–$8,000; for enterprise, $15,000–$50,000+. The LTV:CAC ratio is the standard health check — a ratio below 3:1 signals acquisition economics are likely unsustainable; above 5:1 often indicates under-investment in growth.

Running customer acquisition cost (cac) for Medical Devices & MedTech with Hadrian

Hadrian's agents apply customer acquisition cost (cac) across Clinical specialty society conferences (ACC, ASN, AAOS, AANS, SAGES, DDW — by clinical specialty), Medical device trade publications (MedCity News, MassDevice, Fierce Medtech, Medical Design & Outsourcing), LinkedIn (CMO or Chief Medical Officer at health systems, OR/cath lab directors, surgeon KOLs, Hospital Value Analysis Coordinator), GPO marketing programs (Vizient, Premier, HealthTrust preferred vendor marketing channels), Clinical society exhibit halls and physician education programs (CME-supported symposia around major meetings) for Medical Devices & MedTech companies — tuned to VP Marketing or VP Commercial at a medical device manufacturer (Series C through public); Product Manager responsible for a specific device line; VP Sales or National Accounts Director managing GPO relationships and IDN accounts; at health systems, a Value Analysis Coordinator or Director of Supply Chain evaluating device portfolios; Interventional Cardiologist, Orthopedic Surgeon, or specialty physician as clinical evaluator and champion and run under your approval, alongside every other marketing function.

FAQ

Customer Acquisition Cost (CAC) for Medical Devices & MedTech — common questions

What is a good CAC payback period?

Under 12 months is top-quartile for B2B SaaS. 12–18 months is healthy for most venture-backed growth-stage companies. Above 24 months creates cash flow strain and investor concern unless offset by very high gross retention. For bootstrapped businesses, a payback period under 6 months is often required to sustain growth without external capital.

How does customer acquisition cost (cac) differ for Medical Devices & MedTech companies?

The fundamentals are the same, but Medical Devices & MedTech marketing carries specific constraints — Hospital value analysis committee (VAC) reviews are the primary purchase gate for capital equipment and novel devices — a device that has clinical champion support but fails economic justification (no published cost-effectiveness data, no reimbursement code, no comparable reduction in length of stay) does not get approved and FDA 21 CFR Part 807 (510(k) clearance process); FDA 21 CFR Part 814 (PMA process for Class III devices); FDA Off-Label Promotion prohibition (device labeling and promotion must match cleared indications); Physician Payments Sunshine Act (Open Payments) reporting for physician KOL relationships; Anti-Kickback Statute implications for device incentives; HIPAA for any patient data used in clinical studies; EU MDR (Medical Device Regulation) and IVDR for European device marketing; ISO 13485 quality system certification as marketing credibility signal; GDPR for clinical study and registry data involving EU patients. Hadrian adapts execution to that context automatically.

BUILT BY HADRIAN'S AGENTS

This page was written by Hadrian — the autonomous CMO.

Hadrian runs every channel of your marketing on your live data. See it work on your brand.

Get early access